Newsroom

June 2016

• In The News Jun 20, 2016

  Malaria's deadly comeback

  In an editorial for Project Syndicate, Nick White, Professor of Tropical Medicine at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, and Thierry Diagana, Head of the Novartis Institute…
• 
  Story Jun 16, 2016 Discovery

  Tackling the common denominator in liver disease

  Researchers focus on reversing the scarring that’s common to liver diseases.

• 
  Story Jun 15, 2016 Patient Perspectives

  Migraine: One of the world’s most common diseases

  Did you know migraine is the most common of all neurological disorders? Learn more surprising facts.

• Press release Jun 15, 2016

  Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment

  Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
• Press release Jun 15, 2016

  Novartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten Generation

  Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
• Press release Jun 15, 2016

  Novartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéen

  Novartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
• Press release Jun 10, 2016

  Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder

  EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
• Press release Jun 10, 2016

  Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

  Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1]  RESPONSE-2 complements data…
• In The News Jun 09, 2016

  Novartis Access perspectives: Expanding access to healthcare: What will it really take?

  A Medium post by Steve Davis, CEO of PATH
• 
  Story Jun 09, 2016 Discovery

  Cancer researchers ready to aim for cures

  New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.

• 
  Story Jun 09, 2016 Discovery

  Confidence led this researcher to swim against the current

  A researcher reflects on her successful journey from Venezuela to the US in which she became a doctor, a scientist, and a mother.

• Press release Jun 09, 2016

  New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products

  Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …